Literature DB >> 11062538

Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3.

P Daubersies1, A W Thomas, P Millet, K Brahimi, J A Langermans, B Ollomo, L BenMohamed, B Slierendregt, W Eling, A Van Belkum, G Dubreuil, J F Meis, C Guérin-Marchand, S Cayphas, J Cohen, H Gras-Masse, P Druilhe, L B Mohamed.   

Abstract

In humans, sterile immunity against malaria can be consistently induced through exposure to the bites of thousands of irradiated infected mosquitoes. The same level of protection has yet to be achieved using subunit vaccines. Recent studies have indicated an essential function for intrahepatic parasites, the stage after the mosquito bite, and thus for antigens expressed during this stage. We report here the identification of liver-stage antigen 3, which is expressed both in the mosquito and liver-stage parasites. This Plasmodium falciparum 200-kilodalton protein is highly conserved, and showed promising antigenic and immunogenic properties. In chimpanzees (Pan troglodytes), the primates most closely related to humans and that share a similar susceptibility to P. falciparum liver-stage infection, immunization with LSA-3 induced protection against successive heterologous challenges with large numbers of P. falciparum sporozoites.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11062538     DOI: 10.1038/81366

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  61 in total

Review 1.  Immunogenetics and the design of Plasmodium falciparum vaccines for use in malaria-endemic populations.

Authors:  Magdalena Plebanski; Owen Proudfoot; Dodie Pouniotis; Ross L Coppel; Vasso Apostolopoulos; Graham Flannery
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

2.  Liver stage antigen and malaria.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2004-08-06       Impact factor: 4.599

3.  Transcription status of vaccine candidate genes of Plasmodium falciparum during the hepatic phase of its life cycle.

Authors:  Myriam Bodescot; Olivier Silvie; Anthony Siau; Philippe Refour; Paco Pino; Jean-François Franetich; Laurent Hannoun; Robert Sauerwein; Dominique Mazier
Journal:  Parasitol Res       Date:  2004-02-12       Impact factor: 2.289

Review 4.  Building better T-cell-inducing malaria vaccines.

Authors:  Stephen M Todryk; Michael Walther
Journal:  Immunology       Date:  2005-06       Impact factor: 7.397

5.  Usefulness of the recombinant liver stage antigen-3 for an early serodiagnosis of Plasmodium falciparum infection.

Authors:  Hyeong-Woo Lee; Sung-Ung Moon; Hye-Sun Ryu; Yeon-Joo Kim; Shin-Hyeong Cho; Gyung-Tae Chung; Khin Lin; Byoung-Kuk Na; Yoon Kong; Kyung-Suk Chung; Tong-Soo Kim
Journal:  Korean J Parasitol       Date:  2006-03       Impact factor: 1.341

6.  Mice deficient in interleukin-4 (IL-4) or IL-4 receptor alpha have higher resistance to sporozoite infection with Plasmodium berghei (ANKA) than do naive wild-type mice.

Authors:  Michael Saeftel; Andreas Krueger; Sandra Arriens; Volker Heussler; Paul Racz; Bernhard Fleischer; Frank Brombacher; Achim Hoerauf
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

7.  Advances and challenges in malaria vaccine development.

Authors:  Ruobing Wang; Joseph D Smith; Stefan H I Kappe
Journal:  Expert Rev Mol Med       Date:  2009-12-16       Impact factor: 5.600

8.  Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D.

Authors:  Xiuli Zhang; Florence A Castelli; Xiaoming Zhu; Michele Wu; Bernard Maillère; Lbachir BenMohamed
Journal:  Clin Vaccine Immunol       Date:  2008-07-30

9.  Liver stage antigen 3 isolated from a cDNA library of Plasmodium falciparum erythrocytic stages.

Authors:  Eva M Moyano; Luis Miguel González; Susana Arahuetes; Agustín Benito
Journal:  Parasitol Res       Date:  2007-09-09       Impact factor: 2.289

Review 10.  Plasmodium vivax: who cares?

Authors:  Mary R Galinski; John W Barnwell
Journal:  Malar J       Date:  2008-12-11       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.